Department of Biosurgery and Surgical Technology, Imperial College London, St Mary's Hospital, Praed Street, London, W2 1NY, UK.
Br J Cancer. 2010 Dec 7;103(12):1858-69. doi: 10.1038/sj.bjc.6605984. Epub 2010 Nov 9.
recent decades have seen combination chemoradiotherapy become the standard treatment for anal squamous cell carcinoma (SCC). However, the burden of this disease continues to rise, with only 10% of patients with metastatic disease surviving >2 years. Further insight into tumour characteristics and molecular biology may identify novel therapeutic targets. This systematic review examines current prognostic markers in SCC of the anus.
an extensive literature search was performed to identify studies reporting on biomarkers in anal cancer in the context of clinical outcome following treatment primarily with chemoradiotherapy.
in all, 21 studies were included. A total of 29 biomarkers were studied belonging to 9 different functional classes. Of these biomarkers, 13 were found to have an association with outcome in at least one study. The tumour-suppressor genes p53 and p21 were the only markers shown to be of prognostic value in more than one study.
an array of biomarkers have been identified that correlate with survival following chemoradiotherapy in anal cancer. However, investigators are yet to identify a biomarker that has the ability to consistently predict outcome in this disease. Further studies are needed to elucidate whether these candidate biomarkers demonstrate their optimum value when they serve as targets for new therapeutic strategies.
近几十年来，联合化疗放疗已成为肛门鳞状细胞癌（SCC）的标准治疗方法。然而，这种疾病的负担仍在不断增加，只有 10%的转移性疾病患者存活时间超过 2 年。进一步深入了解肿瘤特征和分子生物学可能会发现新的治疗靶点。本系统评价检查了肛门 SCC 的当前预后标志物。
进行了广泛的文献检索，以确定报告主要采用放化疗治疗后肛门癌生物标志物与临床结局相关的研究。
共纳入 21 项研究。共研究了 29 个生物标志物，属于 9 个不同的功能类别。在这些生物标志物中，有 13 个在至少一项研究中与结局相关。肿瘤抑制基因 p53 和 p21 是唯一在两项以上研究中显示出预后价值的标志物。
已经确定了一系列与肛门癌放化疗后生存相关的生物标志物。然而，研究人员尚未确定一种能够始终如一地预测该疾病结局的生物标志物。需要进一步的研究来阐明这些候选生物标志物是否在作为新治疗策略的靶点时表现出最佳价值。
